Sharing My Perspective on DMD With a Fellow Columnist

This week’s column is a little different than usual. Hawken Miller, a fellow Muscular Dystrophy News columnist who has Duchenne muscular dystrophy (DMD), reached out to collaborate. Hawken, who’s also a features writer for Bionews, the parent company of this website, asked me five questions about being the parent…

Pliant Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) for permission to begin clinical testing of PLN-101325, its experimental therapy for muscular dystrophy, by the end of this year. In preclinical studies involving cell and animal models — the results of which were presented…

The experimental oral therapy EDG-5506 has been generally well-tolerated and lowered markers of muscle damage among men with Becker muscular dystrophy (BMD) in the open-label ARCH clinical trial, early data show. Findings supported the shift to a higher daily treatment dose in study patients. “These interim 2-month ARCH data…

This week’s column will be slightly different than normal. I reached out to fellow Muscular Dystrophy News Today columnist Betty Vertin, who has three boys with Duchenne muscular dystrophy (DMD), ages 16, 13, and 11, to seek her collaboration. I asked Betty five questions about life with Duchenne,…

Some days do not want to be good ones. We had one of those days this past Sunday. I was determined to get to church on time. From the get-go, many factors were working against me. For one, my husband wasn’t home. My son without Duchenne, Chance, is playing…

Defeat Duchenne Canada is investing $1.14 million in three research projects aimed at providing better treatments for Duchenne muscular dystrophy, the most common type of muscular dystrophy and one that affects about 1 in 3,500 male births. The trio of three-year projects joins six other research efforts…

The Muscular Dystrophy Association (MDA) is hosting a one-day games streaming fundraiser, dubbed “MDA Rivals,” this Saturday, June 18. The event, streaming on MDA’s Twitch channel, will feature stars from MDA Let’s Play — a platform that aims to raise funds for MDA and awareness about muscular…

The seasons are all special to me and necessary to one another. Each holds its own challenges and wonder. Here in Nebraska, we are fortunate enough to experience all four — winter, spring, summer, and fall. Every time I enter a new season, I think it’s my favorite, but by…

FibroGen has completed patient enrollment for its Phase 3 trial evaluating pamrevlumab in combination with corticosteroids as a potential treatment for children with Duchenne muscular dystrophy (DMD). The LELANTOS-2 study (NCT04632940) has enrolled 73 boys with DMD, ages 6 to 12, who maintain their ability to walk.

Reduced heart function is associated with a higher rate of mortality among people with Duchenne muscular dystrophy (DMD), a new study reports. Results, however, did not suggest that reduced heart function is an independent predictor of survival for DMD patients. Instead, analyses indicated patients who took diuretics or who…